Annual Reports in Medicinal Chemistry

Annual Reports in Medicinal Chemistry

1st Edition - October 25, 2010

Write a review

  • Editor: John Macor
  • Paperback ISBN: 9780123809025
  • eBook ISBN: 9780123809032

Purchase options

Purchase options
DRM-free (PDF)
Sales tax will be calculated at check-out

Institutional Subscription

Free Global Shipping
No minimum order


Annual Reports in Medicinal Chemistry provides timely and critical reviews of important topics in medicinal chemistry together with an emphasis on emerging topics in the biological sciences, which are expected to provide the basis for entirely new future therapies.

Key Features

  • Covers findings related to cardiovascular, inflammation, and pulmonary diseases
  • Examines issues in oncology, from mTor inhibitors to drug targets
  • Incorporates up-to-date information on drug design and discovery, including delivery to market


medicinal, pharmaceutical, and organic chemists

Table of Contents

  • Section I: Central Nervous System Diseases – ROBICHAUD

    1. Voltage-Gated Calcium Channel Antagonists for the Central Nervous System
    2. James C. Barrow and Joseph L. Duffy

    3. Recent Developments in Glycine Transporter-1 Inhibitors
    4. Christopher L. Cioffi, Shuang Liu and Mark A.Wolf

    5. Modulators of Transient Receptor Potential Ion Channels
    6. Rajagopal Bakthavatchalam and S. David Kimball

    7. Defining Neuropharmacokinetic Parameters in CNS Drug Discovery to Determine Cross-species Pharmacologic Exposure-Response Relationships
    8. Christopher L. Shaffer

      Section II: Cardiovascular and Metabolic Diseases - STAMFORD

    9. High Affinity Niacin Receptor GPR109A Agonists
    10. Hong C. Shen and Steven L. Colletti

    11. Recent Advances in Acetyl CoA Carboxylase (ACC) Inhibitors
    12. Matthew P. Bourbeau, John G. Allen, and Wei Gu

    13. Enzymatic Targets in the Triglyceride Synthesis Pathway
    14. Dmitry O. Koltun and Jeff Zablocki

    15. Inhibitors of HIF Prolyl Hydroxylases
    16. Michael H. Rabinowitz, Terrance D. Barrett, Mark D. Rosen, Hariharan Venkatesan

      Section III: Inflammation / Pulmonary / GI - BARRISH/Weinstein

    17. Opioid Receptor Antagonists for Gastrointestinal Dysfunction
    18. R. William Hipkin and Roland E. Dolle

    19. CFTR Modulators for the Treatment of Cystic Fibrosis
    20. Sabine Hadida, Frederick Van Goor and Peter D. J. Grootenhuis

    21. Targeting B-cells in inflammatory disease
    22. Kevin S. Currie

    23. Modulators of Toll-Like Receptor (TLR) Signaling
    24. Mark Spyvee, Lynn Hawkins, and Sally Ishizaka

      Section IV: Oncology - McAlpine

    25. Janus Kinase 2 (JAK2) inhibitors for the treatment of myeloproliferative neoplasm (MPN)
    26. Ashok V. Purandare, Matthew V. Lorenzi and Louis J. Lombardo

    27. Development of poly(ADP-ribose)polymerase (PARP) inhibitors in oncology
    28. Philip Jones

    29. Epigenetic Targets and Cancer Drug Discovery
    30. Patrick M. Woster, Ph.D

      Section V: Infectious Diseases - Primeau

    31. HIV-1 Integrase Strand Transfer Inhibitors
    32. Brian A. Johns

    33. Recent Advances in Drug Discovery for Neglected Tropical Diseases Caused by Infective Kinetoplastid Parasites
    34. Robert T. Jacobs and Charles Ding

    35. Recent Advances in the Inhibition of Bacterial Fatty Acid Biosynthesis
    36. Vincent Gerusz

      Section VI: Topics in Biology - LOWE

    37. Back to the Plaque: Emerging Studies That Re-Focus Attention on the Neuritic Plaque in Alzheimer’s Disease
    38. Dr. Robert B. Nelson

    39. Targeting Methyl Lysine
    40. Stephen V. Frye, Tom Heightman and Jian Jin

    41. Chemical Proteomic Technologies for Drug Target Identification
    42. Kieran F. Geoghegan and Douglas S. Johnson

    43. NIH Translational Programs for Assisting Pre-Clinical Drug Discovery and Development
    44. Raj N. Misra

      Section VII: Topics in Drug Design and Discovery - DESAI

    45. Role of Physicochemical Properties and Lipophilic Ligand Efficiency (LipE or LLE) in addressing Drug Safety Risks
    46. Martin P. Edwards and David A. Price

    47. Reducing the Risk of Drug Attrition Associated with Physicochemical Properties
    48. Paul D. Leeson and James R. Empfield

    49. Compound Collection Enhancement and Paradigms for High Throughput Screening - an Update
    50. Stevan W Djuric, Irini Akritopoulou-Zanze, Philip B Cox and Scott Galasinski

    51. The Role of Fluorine in the Discovery and Optimization of CNS Agents: Modulation of Drug-Like Properties
    52. Kevin J. Hodgetts, Kerry J. Combs, Amy M. Elder and Geraldine C. Harriman

    53. Patents in Drug Discovery: Case Studies, Examples, and Simple Steps Medicinal Chemists Can Take to Protect Hard-Won Intellectual Property
    54. Charles J. Andres, Jr. and Richard L. Treanor

      Section VIII: Trends and Perspectives

    55. To Market, To Market – 2009

    Shridhar Hegde and Michelle Schmidt

Product details

  • No. of pages: 648
  • Language: English
  • Copyright: © Academic Press 2010
  • Published: October 25, 2010
  • Imprint: Academic Press
  • Paperback ISBN: 9780123809025
  • eBook ISBN: 9780123809032

About the Series Editor

John Macor

Affiliations and Expertise

Neuroscience Discovery Chemistry, Bristol-Myers Squibb, USA

Ratings and Reviews

Write a review

There are currently no reviews for "Annual Reports in Medicinal Chemistry"